KVUEConsumer Defensive · Household & Personal ProductsThe 14 Wall Street analysts covering Kenvue, Inc. hold a median 12-month price target of $19 — -0.3% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 65 of 100 as at 22 Aug 2026 — in the upper half.
Consensus tells you what everyone already believes. The model scores Kenvue, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Volatility (92): The share price has been relatively steady.
Revisions (51): Analysts have, on balance, been cutting their forecasts.
Size (7): Larger than most of the companies we track — more scrutinised, less often mispriced.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on KVUE, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
The green dot is the last close — the median target sits −0.3% from it.
Of the 20 most recent actions, 2 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 11 Aug 2026 | UBS | Maintains | Neutral | $20 → $19 |
| 21 July 2026 | Barclays | Maintains | Equal-Weight | $18 → $19 |
| 21 July 2026 | Barclays | Maintains | Equal-Weight | — |
| 16 July 2026 | UBS | Maintains | Neutral | $18 → $20 |
| 16 July 2026 | UBS | Maintains | Neutral | — |
| 15 Apr 2026 | Citigroup | Maintains | Neutral | $20 → $19 |
| 15 Apr 2026 | Citigroup | Maintains | Neutral | — |
| 14 Apr 2026 | Barclays | Maintains | Equal-Weight | $19 → $18 |
| 14 Apr 2026 | Barclays | Maintains | Equal-Weight | — |
| 7 Apr 2026 | UBS | Maintains | Neutral | — |
| 6 Mar 2026 | Barclays | Maintains | Equal-Weight | — |
| 18 Feb 2026 | Canaccord Genuity | Maintains | Hold | — |
| 18 Feb 2026 | Citigroup | Maintains | Neutral | — |
| 18 Feb 2026 | UBS | Maintains | Neutral | — |
| 30 Jan 2026 | Jefferies | Downgrade | Hold | — |
| 10 Nov 2025 | Barclays | Maintains | Equal-Weight | — |
| 29 Oct 2025 | Canaccord Genuity | Downgrade | Hold | — |
| 27 Oct 2025 | Jefferies | Maintains | Buy | — |
| 10 Oct 2025 | JP Morgan | Maintains | Overweight | — |
| 9 Oct 2025 | Citigroup | Maintains | Neutral | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. KVUE appears on the weeks it earns a place.
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 35% of US stocks
Cheaper than 49% of US stocks
Cheaper than 31% of US stocks
Cheaper than 30% of US stocks
Higher than 34% of US stocks
Higher than 46% of US stocks
Higher than 72% of US stocks
Higher than 78% of US stocks
Higher than 71% of US stocks
Higher than 75% of US stocks
Higher than 85% of US stocks
Higher than 80% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Kenvue, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Kimberly-Clark appointed Suzana Blades as Senior Vice President and General Counsel, effective September 1, 2026, reporting to Jeff Melucci and joining the Executive Leadership Team.
Why it matters — KVUE watchers may track competitor Kimberly-Clark's leadership changes as part of broader industry context.
Kenvue's (KVUE) second-quarter sales and earnings missed estimates, but the company reported improved organic growth as Skin Health and Beauty segments led a broader recovery.
Why it matters — KVUE watchers would care because the results show a mixed quarter—missing estimates yet signalling momentum in organic growth with strong performance from key segments.
Kenvue shares closed at $19.18 on August 6, falling 2.5% after the consumer health company reported a rare earnings miss. The article examines how Reddit users and Wall Street are viewing the company as a potential buyout approaches.
Why it matters — KVUE watchers would care because the earnings miss and buyout speculation could influence how the market prices the company ahead of a possible acquisition.
Kenvue reported higher second-quarter sales and earnings, but both fell short of estimates as inflation, tariffs and foreign exchange pressure margins.
Why it matters — A KVUE watcher would care because these results signal margin pressure from inflation, tariffs and foreign exchange even as revenue grows.
Kenvue reported second-quarter results that narrowly missed Wall Street expectations, with adjusted diluted earnings per share of $0.31 versus the $0.32 consensus estimate. Margins declined from a year earlier, and shares fell about 2% on the news.
Why it matters — KVUE watchers would care because a quarterly earnings miss and year-over-year margin decline could signal softening in the consumer health company's financial performance.
The 14 Wall Street analysts covering Kenvue, Inc. have a median 12-month price target of $19, with estimates ranging from $18 to $23. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 14 analysts covering Kenvue, Inc., 2 rate it a Buy, 12 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Kenvue, Inc. 65 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Kenvue, Inc. ranks 65 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Volatility (92 of 100).
No one can know that. What the data says: the median 12-month target from 14 analysts implies -0.3% from the last close, and Ticker Nerd's factor model ranks Kenvue, Inc. 65 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Kenvue, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for KVUE are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $18 to $23 over the next 12 months.
Kenvue, Inc. returned -6.9% over the 12 months to 21 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Kenvue Inc. is a global consumer health company focused on over-the-counter medicines, personal care, and wellness products for everyday use.
The most recent item we track (PRNewsWire, 13 Aug 2026): "Kimberly-Clark Appoints Suzana Blades as Senior Vice President and General Counsel". Kimberly-Clark appointed Suzana Blades as Senior Vice President and General Counsel, effective September 1, 2026, reporting to Jeff Melucci and joining the Executive Leadership Team.
Kenvue Inc. is a global consumer health company focused on over-the-counter medicines, personal care, and wellness products for everyday use. Headquartered in Summit, New Jersey, Kenvue develops and markets a broad portfolio of well-known brands across categories such as pain relief, allergy care, cough and cold, digestive health, baby care, skincare, and oral care. Its products include widely recognized names such as Tylenol, Zyrtec, Benadryl, Neutrogena, Aveeno, Listerine, Johnson’s, Band-Aid, and Visine, which are distributed through pharmacies, mass retailers, e-commerce platforms, and healthcare channels worldwide. Kenvue’s business is organized around meeting consumer needs in self-care and daily health routines, offering non-prescription solutions that support hygiene, symptom relief, and skin and hair health. By combining brand recognition, large-scale distribution, and consumer insight-driven product development, Kenvue plays a significant role in the consumer health market, serving households, caregivers, and professionals across multiple regions.
CEO Mr. Kirk L. Perry · 21,780 employees · United States · https://www.kenvue.com